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 Patient: Female, 14
 Final Diagnosis: Pulmonary embolism
 Symptoms: Chest pain • dyspnea • syncope 
 Medication: Combined oral contraceptives 
 Clinical Procedure: —
 Specialty: Internal Medicine
 Objective: Adverse events of drug therapy
 Background: The prothrombotic effect of combined oral contraceptives (COCs) is well-established, with a 3–6-fold increased 
risk of VTE compared to non-users. When initiation of COCs is considered, it is therefore of paramount im-
portance to carefully evaluate all other potential risk factors for VTE. Based on a case of life-threatening COC-
associated pulmonary embolism in a girl heterozygous for the prothrombin G20210A mutation and with a fam-
ily history of thrombotic disease, we discuss the importance of assessing not just the genotype but also the 
phenotype when considering initiation of COCs in patients with thrombophilia.
 Case Report: A 14-year-old girl presented with acute onset of chest pain and dyspnea followed by syncope. She was hypox-
ic and hemodynamically compromised at admission. Computed tomography pulmonary angiography revealed 
a large central “saddle” pulmonary embolism causing nearly total occlusion of the right pulmonary artery, and 
several minor peripheral embolisms bilaterally. She was successfully treated with thrombolysis (alteplase) fol-
lowed by aPTT-adjusted heparin infusion until adequate anticoagulation with warfarin was achieved.
  Two years earlier, the patient had been found heterozygote for the prothrombin G20210A mutation, and 9 
months before admission she had initiated use of second-generation COCs.
 Conclusions: Hereditary thrombophilia and a family history of early-onset venous thromboembolism (VTE) each pose an in-
creased risk of VTE and should be considered as separate, irreversible risk factors. Other contraceptive meth-
ods should be used when treatment with COCs is expected to result in an unacceptable high risk of VTE.
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Background
Combined oral contraceptives (COCs) are associated with a 
3-6 times higher risk of venous thromboembolism (VTE) com-
pared to non-users [1,2]. Likewise, hereditary thrombophilia 
increases VTE risk, some more than other [3]. Persons hetero-
zygous of the prothrombin G20210A mutation have a 3-fold 
increased risk of VTE [4]. Accordingly, this thrombophilia is gen-
erally classified as a minor risk factor for thrombosis [5] and, 
therefore, some consider this only as a relative, not absolute, 
contraindication for COC-use [6,7].
However, based on a case of massive pulmonary embolisms in 
a COC-using girl heterozygous for the prothrombin G20210A 
mutation and with familial disposition for thrombotic disease, 
we aim to emphasize the importance of assessing not just the 
genotype but also the phenotype when considering initiation 
of COCs in patients with thrombophilia.
Case Report
A 14-year-old, normal-weight, non-smoking, white girl presented 
with acute onset of chest pain and dyspnea followed by synco-
pe. She was transported to the hospital by ambulance, where 
she was found hypoxic (saturation 87%), tachycardic (heart rate 
125), and hypotensive (systolic BP <100 mmHg). Acute echo-
cardiography was performed (Video 1) and revealed dilatation 
of the right ventricle (“D-configuration”), pulmonary hyperten-
sion (tricuspid regurgitation pressure gradient 50 mm Hg), and 
reduced pulmonary blood flow. A highly elevated D-dimer (16.1 
mg/L) and a moderate increase in Troponin T (243 ng/L) was 
found. Computed tomography pulmonary angiography revealed 
a large central “saddle” pulmonary embolism causing nearly 
total occlusion of the right pulmonary artery (Figure 1), and 
several minor peripheral embolisms bilaterally. Physical exam-
ination was without clinical signs of deep venous thrombosis.
Because the patient was hemodynamically compromised, 
thrombolytic treatment with alteplase was initiated and fol-
lowed by aPTT-adjusted heparin infusion. After termination 
of the infusion, low molecular weight heparin was initiated 
and continued until adequate anticoagulation with warfarin 
was achieved. Clinical treatment effect was observed within 
a few hours, and echocardiography on day 2 confirmed that 
the pulmonary pressure was reduced. At discharge on day 3, 
the patient was hemodynamically stable (BP 120/70 mm Hg, 
HR 85, and saturation 98%) with only a minor sensation of 
respiratory distress.
Due to several cases of both arterial and venous thrombosis at 
young age in at least 2 generations of the family, the patient 
had been tested for hereditary thrombophilia 2 years earlier; 
she was heterozygote for the prothrombin G20210A muta-
tion. Due to severe menstrual bleedings, she had initiated use 
of second-generation COCs containing 250 µg norgestimate 
and 35 µg ethinylestradiol once daily 9 months before admis-
sion. The use of this contraceptive was discontinued at admis-
sion, and she was strictly advised to never resume treatment.
Discussion
COC-users heterozygote for the prothrombin G20210A mu-
tation have been found to have a 7–10-fold increased risk of 
VTE, with the risk being highest early in the course of COC 
use [8–10]. This combination thus results in an at least additive 
and maybe even a synergistic prothrombotic effect. Whether 
the risk is further increased in individuals who additionally have 
Video 1.  Echocardiogram showing dilatation of the right 
ventricle.
Figure 1.  Computed tomography showing a large ‘saddle’ 
embolus occluding the right pulmonary artery.
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a thrombophilic phenotype is not known. However, a positive 
family history, defined as a documented VTE in a first-degree 
relative, is an established individual risk factor for VTE (3-fold 
VTE risk) [9] and is therefore assumed to also be important in 
individuals with hereditary thrombophilia [5].
Current WHO guidelines advise against use of COCs in females 
with any known prothrombotic mutation [11]. However, sever-
al clinicians advocate that an individualized risk assessment 
where several risk factors, including the specific thrombophil-
ia, age, and individual and family history of VTE, should be tak-
en into consideration when counseling females with thrombo-
philia about contraceptive use [5,7,10]. Low-risk thrombophilia 
alone, such as the prothrombin G20210A mutation, is consid-
ered by some to be a relative, but not absolute, contraindica-
tion for COC use [6,7]. However, as emphasized by this case 
report, it is important to consider not just the inherited gen-
otype but also the inherited phenotype when evaluating the 
risk of thrombosis. Since a prothrombotic genotype does not 
necessarily result in a prothrombotic phenotype, and vice ver-
sa, they should be considered as separate and potentially in-
teracting risk factors [3,5,10]. Unprovoked venous thrombosis 
in a first-degree relative occurring before 50 years of age in-
dicate a strongly thrombophilic phenotype, and should there-
fore be considered a relative contraindication for COC use, re-
gardless of the patient´s genotype [5].
The family history of our patient indicated a strongly throm-
bophilic phenotype, which in combination with the prothrom-
botic effects of both the mutation and COCs resulted in a life-
threatening major thrombotic event. Future treatment with 
COCs or other types of estrogen-containing hormonal prepa-
rations (i.e., hormone replacement therapy) is contraindicat-
ed. Non-hormonal methods or oral progestin-only contracep-
tives should be preferred in this patient and others where 
treatment with COCs is expected to impose an unacceptably 
high risk of VTE [11,12].
Current evidence does not support anticoagulant therapy of 
higher intensity or longer duration than normal when treat-
ing VTE patients with the prothrombin G20210A mutation [5]. 
Our patient was thus started on warfarin with target INR 2.0-
3.0 and planned duration of 12 months [13]. A non-vitamin K 
antagonist oral anticoagulant (NOAC; dabigatran, rivaroxaban, 
or apixaban) might be an equally effective and safe treatment 
compared to warfarin in this patient [13,14]. However, patients 
with pulmonary embolism treated with thrombolysis were not 
included in phase III trials on NOACs, and data on long-term 
prophylaxis and treatment of VTE with NOACs are warranted.
Conclusions
Initiation of COCs should be based on individualized risk as-
sessment with all potential risk factors for VTE, including both 
genotype (if available) and phenotype, taken into account. Other 
contraceptive methods should be considered in patients with 
an increased risk of VTE.
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